Lennart Mucke’s lab focuses on how major neurological and psychiatric conditions, such as Alzheimer’s disease and autism spectrum disorders, cause cognitive deficits, behavioral abnormalities, and other disabling symptoms. They study people afflicted by these conditions, as well as related mouse and cell culture models, to unravel disease mechanisms and identify novel therapeutic strategies. The group’s ultimate goal is to advance the understanding of devastating brain disorders to a point where transformative treatments can be developed for their prevention, control, and reversal.
Disease Areas
Alzheimer’s Disease
Autism Spectrum Disorders
Epilepsy
Other Dementias
Areas of Expertise
Creation and Direction of Interdisciplinary Research Programs
Development and Preclinical Assessment of Novel Therapeutic Strategies
Dissection of Complex Pathogenic Pathways in Mouse Models
Pathobiology of Amyloid Proteins and Tau
Role of Glia in Health and Disease
Training of Leaders in Disease-Focused Neuroscience
Lab Focus
Mechanisms and pathogenic impact of neural network dysfunction and DNA damage in Alzheimer’s disease and related conditions.
Understanding the roles of tau and glial cells in health and disease.
Therapeutic strategies targeting tau or other molecules that promote neuronal impairments in major neurological and psychiatric disorders.
Research Impact
Mucke’s studies revealed that Aβ and apoE4 can elicit neuronal deficits independently of amyloid plaques and that Aβ causes not only synaptic depression, but also neural network hyperexcitability. He discovered that reducing neuronal tau levels prevent network hyperexcitability of diverse causes and is well tolerated, revealing a novel role for tau in the regulation of neuronal activity and challenging the long-standing notion that tau aggregation causes neurodegeneration through loss of tau functions.
These discoveries paved the path toward the development of tau-lowering therapeutics, which is now pursued in academic laboratories and pharmaceutical companies around the world. Mucke’s investigations of patients with Alzheimer’s and related models also shed new light on the intriguing overlap between Alzheimer’s disease and epilepsy, culminating in the discoveries that a substantial proportion of Alzheimer’s patients have subclinical, non-convulsive epileptiform activity and that the suppression of such activity in animal models can reverse synaptic and cognitive deficits. These insights provided critical guidance for the design of ongoing clinical trials aimed at reversing network dysfunction in early stages of Alzheimer’s disease. Mucke has advanced this field from its traditional focus on morphological changes toward an understanding of Alzheimer’s disease at the synaptic and neural network level and identified novel therapeutic strategies in a field in desperate need of them. In addition, he has developed novel strategies to expedite the translation of scientific discoveries into better treatments for diseases that are frequent, devastating, and costly to populations around the world.
Related News
Zeroing in on a New Treatment for Autism and Epilepsy
Gladstone scientists show that reducing levels of the protein tau soon after birth can prevent these conditions in an experimental model
Alzheimer’s Disease May Cause Vicious Circle between Brain Network and Immune Cell Dysfunctions
Gladstone scientists identified treatments to block subtle epileptic activity and chronic brain inflammation in a mouse model of Alzheimer’s disease
Maintaining Balance in the Brain
Gladstone scientists help explain how reducing the protein tau can prevent abnormal brain activity associated with Alzheimer’s disease, autism, and epilepsy
Gladstone Neuroscience Researcher Elected to the National Academy of Medicine
Lennart Mucke is recognized for his pioneering discoveries in research on Alzheimer’s disease and related disorders
CNDAP Partners with Takeda to Develop New Therapies for Alzheimer’s Disease and Related Brain Disorders
A research collaboration to target the protein tau with small molecules
Meet Gladstone: Randi Mott
Randi Mott was born in New Jersey but grew up in Florida. She has an extensive orchid collection and would like to meet Austrian zoologist Paul Pfurtscheller
Leading the Way to Better Treatments for People with Epilepsy
Gladstone researchers harness unique tools and perspectives to study life-threatening seizures that lack a cure
Young Scientists Committed to Finding Treatments for Neurodegenerative Diseases
The 2020 Berkelhammer Scholars break new ground in research on dementias, Parkinson’s disease, and neuropsychiatric disorders
Current and Future Strategies to Treat and Prevent Alzheimer’s Disease
With an estimated 44 million diagnosed with Alzheimer’s disease worldwide, research is moving quickly to better understand the disease.
Bay Area Labs Fighting Coronavirus, Sometimes Leaving Regular Work Aside
San Francisco Chronicle—The COVID-19 pandemic has disrupted many industries, including biomedical research. Senior Investigators Warner Greene and Lennart Mucke describe how some labs have shifted the focus of their work to…
Autism Symptoms Improved in Mice by Reducing Alzheimer’s Disease Protein
GEN—Genetic Engineering and Biotechnology News reports on a recent study from the lab of Lennart Mucke that shows how reducing levels of Tau, a protein associated with Alzheimer’s disease, could prevent…
Alzheimer’s Protein Turns up as Potential Target for Autism Treatments
Spectrum—Lowering the levels of a protein called tau, best known for its involvement in Alzheimer’s disease, eases autism-like traits in mice, according to a study from the lab of Lennart Mucke.
Suppressing Alzheimer’s Protein Prevents Autism Symptoms in Mouse Model
Technology Networks—A recent study from Senior Investigator Lennart Mucke and his team show how a protein related to Alzheimer’s disease could play a role in autism.
Could Targeting an Alzheimer’s-Associated Protein Prevent Autism?
New study shows reducing levels of the protein tau prevents core autism symptoms in animal models
Evolution of Research
Gladstone started as a single institute in 1979 but has since grown to four institutes which use cutting-edge technology to tackle cardiovascular, neurological, and immunological diseases.
Professional Titles
Director, Gladstone Institute of Neurological Disease
Senior Investigator, Gladstone Institutes
Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology, UC San Francisco
Bio
Lennart Mucke is the director of the Gladstone Institute of Neurological Disease, and a senior investigator at Gladstone. He is also the Joseph B. Martin Distinguished Professor of Neuroscience and a professor of neurology at UC San Francisco (UCSF). He has joint appointments in UCSF’s Neuroscience, Biomedical Sciences, and Medical Scientist (MD/PhD) Graduate Training Programs.
Mucke is a graduate of the Georg-August University and the Max Planck Institute for Biophysical Chemistry (Neurobiology) in Göttingen, Germany. He trained in internal medicine at the Cleveland Clinic, in neurology at Massachusetts General Hospital and Harvard Medical School, and in neuroimmunology and neurovirology at The Scripps Research Institute, where he was subsequently appointed to the faculty. Mucke was recruited to Gladstone Institutes in 1996.
How Did You Get Your Start in Science?
“I developed a great interest in psychiatry, neurology, and neuroscience in high school and to this day can’t think of anything more fascinating and rewarding than to discover how the brain works and how to preserve the fragile structures that harbor the very essence of who we are.”
Lennart Mucke, MD
Honors and Awards
2019 Fellow of the German Center for Neurodegenerative Diseases (DZNE)
2013 MetLife Award for Medical Research in Alzheimer’s Disease, MetLife Foundation
2013 American Pacesetter Award, ARCS Foundation
2013 J. Elliott Royer Award for Excellence in Academic Neurology, UC San Francisco
2012 Khalid Iqbal Lifetime Achievement Award in Recognition of Outstanding Research, Alzheimer’s Association
2012 Honorary Citizen of New Orleans
2011 Chancellor’s Award in Neurosciences, Louisiana State University
2010 Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases, American Academy of Neurology
2007 Award for Excellence in Direct Teaching and/or Excellence in Mentoring and Advising, Haile T. Debas Academy of Medical Educators
2006 Arthur Cherkin Memorial Award, UCLA
2003 Promising Investigator Award, MetLife Foundation
2003 Elected to the Association of American Physicians
1999 Zenith Award, Alzheimer’s Association
1998 Elected to the American Neurological Association
Publications
- TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model. Shao E, Chang CW, Li Z, Yu X, Ho K, Zhang M, Wang X, Simms J, Lo I, Speckart J, Holtzman J, Yu GQ, Roberson ED, Mucke L. Sci Transl Med. 2022 Apr 27; 14(642):eabm5527.
- Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial. Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM, Venkateswaran N, Koestler M, Zhang W, Mucke L, Howell MJ, Possin KL, Kramer JH, Boxer AL, Miller BL, Nagarajan SS, Kirsch HE. JAMA Neurol. 2021 11 01; 78(11):1345-1354.
- Tau reduction affects excitatory and inhibitory neurons differently, reduces excitation/inhibition ratios, and counteracts network hypersynchrony. Chang CW, Evans MD, Yu X, Yu GQ, Mucke L. Cell Rep. 2021 10 19; 37(3):109855.
- Interdependence of neural network dysfunction and microglial alterations in Alzheimer's disease-related models. Das M, Mao W, Shao E, Tamhankar S, Yu GQ, Yu X, Ho K, Wang X, Wang J, Mucke L. iScience. 2021 Nov 19; 24(11):103245.
- Phenotypic Differences between the Alzheimer's Disease-Related hAPP-J20 Model and Heterozygous Zbtb20 Knock-Out Mice. Gulbranson DR, Ho K, Yu GQ, Yu X, Das M, Shao E, Kim D, Zhang WJ, Choudhary K, Thomas R, Mucke L. eNeuro. 2021 May-Jun; 8(3).
- Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Chang CW, Shao E, Mucke L. Science. 2021 02 26; 371(6532).
- Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies Che-Wei Chang, Eric Shao, Lennart Mucke. . Science. 2021; 371(6532):eabb8255.
- Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1. Johnson ECB, Ho K, Yu GQ, Das M, Sanchez PE, Djukic B, Lopez I, Yu X, Gill M, Zhang W, Paz JT, Palop JJ, Mucke L. Mol Neurodegener. 2020 09 14; 15(1):53.
- A second X chromosome contributes to resilience in a mouse model of Alzheimer's disease. Davis EJ, Broestl L, Abdulai-Saiku S, Worden K, Bonham LW, Miñones-Moyano E, Moreno AJ, Wang D, Chang K, Williams G, Garay BI, Lobach I, Devidze N, Kim D, Anderson-Bergman C, Yu GQ, White CC, Harris JA, Miller BL, Bennett DA, Arnold AP, De Jager PL, Palop JJ, Panning B, Yokoyama JS, Mucke L, Dubal DB. Sci Transl Med. 2020 08 26; 12(558).
- Long-term potentiation is independent of the C-tail of the GluA1 AMPA receptor subunit. Díaz-Alonso J, Morishita W, Incontro S, Simms J, Holtzman J, Gill M, Mucke L, Malenka RC, Nicoll RA. Elife. 2020 08 24; 9.
- Tau Reduction Prevents Key Features of Autism in Mouse Models. Tai C, Chang CW, Yu GQ, Lopez I, Yu X, Wang X, Guo W, Mucke L. Neuron. 2020 05 06; 106(3):421-437.e11.
- Early neuronal accumulation of DNA double strand breaks in Alzheimer's disease. Shanbhag NM, Evans MD, Mao W, Nana AL, Seeley WW, Adame A, Rissman RA, Masliah E, Mucke L. Acta Neuropathol Commun. 2019 05 17; 7(1):77.
- Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer's Disease Model. Merlini M, Rafalski VA, Rios Coronado PE, Gill TM, Ellisman M, Muthukumar G, Subramanian KS, Ryu JK, Syme CA, Davalos D, Seeley WW, Mucke L, Nelson RB, Akassoglou K. Neuron. 2019 03 20; 101(6):1099-1108.e6.
- Klotho controls the brain-immune system interface in the choroid plexus. Zhu L, Stein LR, Kim D, Ho K, Yu GQ, Zhan L, Larsson TE, Mucke L. Proc Natl Acad Sci U S A. 2018 11 27; 115(48):E11388-E11396.
- Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Ryu JK, Rafalski VA, Meyer-Franke A, Adams RA, Poda SB, Rios Coronado PE, Pedersen LØ, Menon V, Baeten KM, Sikorski SL, Bedard C, Hanspers K, Bardehle S, Mendiola AS, Davalos D, Machado MR, Chan JP, Plastira I, Petersen MA, Pfaff SJ, Ang KK, Hallenbeck KK, Syme C, Hakozaki H, Ellisman MH, Swanson RA, Zamvil SS, Arkin MR, Zorn SH, Pico AR, Mucke L, Freedman SB, Stavenhagen JB, Nelson RB, Akassoglou K. Nat Immunol. 2018 11; 19(11):1212-1223.
- The mouse as a model for neuropsychiatric drug development. Howe JR, Bear MF, Golshani P, Klann E, Lipton SA, Mucke L, Sahin M, Silva AJ. Curr Biol. 2018 09 10; 28(17):R909-R914.
- The Psychiatric Cell Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular Pathways in Neuropsychiatric Disorders. Willsey AJ, Morris MT, Wang S, Willsey HR, Sun N, Teerikorpi N, Baum TB, Cagney G, Bender KJ, Desai TA, Srivastava D, Davis GW, Doudna J, Chang E, Sohal V, Lowenstein DH, Li H, Agard D, Keiser MJ, Shoichet B, von Zastrow M, Mucke L, Finkbeiner S, Gan L, Sestan N, Ward ME, Huttenhain R, Nowakowski TJ, Bellen HJ, Frank LM, Khokha MK, Lifton RP, Kampmann M, Ideker T, State MW, Krogan NJ. Cell. 2018 07 26; 174(3):505-520.
- Neuronal levels and sequence of tau modulate the power of brain rhythms. Das M, Maeda S, Hu B, Yu GQ, Guo W, Lopez I, Yu X, Tai C, Wang X, Mucke L. Neurobiol Dis. 2018 09; 117:181-188.
- Nav1.1-Overexpressing Interneuron Transplants Restore Brain Rhythms and Cognition in a Mouse Model of Alzheimer's Disease. Martinez-Losa M, Tracy TE, Ma K, Verret L, Clemente-Perez A, Khan AS, Cobos I, Ho K, Gan L, Mucke L, Alvarez-Dolado M, Palop JJ. Neuron. 2018 04 04; 98(1):75-89.e5.
- Istradefylline reduces memory deficits in aging mice with amyloid pathology. Orr AG, Lo I, Schumacher H, Ho K, Gill M, Guo W, Kim DH, Knox A, Saito T, Saido TC, Simms J, Toddes C, Wang X, Yu GQ, Mucke L. Neurobiol Dis. 2018 02; 110:29-36.
- The integration site of the APP transgene in the J20 mouse model of Alzheimer's disease. Tosh JL, Rickman M, Rhymes E, Norona FE, Clayton E, Mucke L, Isaacs AM, Fisher EMC, Wiseman FK. Wellcome Open Res. 2017; 2:84.
- Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture. Miyamoto T, Stein L, Thomas R, Djukic B, Taneja P, Knox J, Vossel K, Mucke L. Mol Neurodegener. 2017 05 19; 12(1):41.
- Network abnormalities and interneuron dysfunction in Alzheimer disease. Palop JJ, Mucke L. Nat Rev Neurosci. 2016 12; 17(12):777-792.
- Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, Darwish SM, Van Berlo V, Barnes DE, Mantle M, Karydas AM, Coppola G, Roberson ED, Miller BL, Garcia PA, Kirsch HE, Mucke L, Nagarajan SS. Ann Neurol. 2016 12; 80(6):858-870.
- Tau Phosphorylation-Much More than a Biomarker. Maeda S, Mucke L. Neuron. 2016 Oct 19; 92(2):265-267.
- Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. Maeda S, Djukic B, Taneja P, Yu GQ, Lo I, Davis A, Craft R, Guo W, Wang X, Kim D, Ponnusamy R, Gill TM, Masliah E, Mucke L. EMBO Rep. 2016 04; 17(4):530-51.
- DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Suberbielle E, Djukic B, Evans M, Kim DH, Taneja P, Wang X, Finucane M, Knox J, Ho K, Devidze N, Masliah E, Mucke L. Nat Commun. 2015 Nov 30; 6:8897.
- Increasing the Receptor Tyrosine Kinase EphB2 Prevents Amyloid-β-induced Depletion of Cell Surface Glutamate Receptors by a Mechanism That Requires the PDZ-binding Motif of EphB2 and Neuronal Activity. Miyamoto T, Kim D, Knox JA, Johnson E, Mucke L. J Biol Chem. 2016 Jan 22; 291(4):1719-1734.
- Network dysfunction in α-synuclein transgenic mice and human Lewy body dementia. Morris M, Sanchez PE, Verret L, Beagle AJ, Guo W, Dubal D, Ranasinghe KG, Koyama A, Ho K, Yu GQ, Vossel KA, Mucke L. Ann Clin Transl Neurol. 2015 11; 2(11):1012-28.
- Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, Mucke L. Nat Neurosci. 2015 Aug; 18(8):1183-9.
- Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β. Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, Ho K, Kim DH, Yu GQ, Mucke L. J Cell Biol. 2015 May 11; 209(3):419-33.
- Dynamin-related protein 1 is required for normal mitochondrial bioenergetic and synaptic function in CA1 hippocampal neurons. Shields LY, Kim H, Zhu L, Haddad D, Berthet A, Pathak D, Lam M, Ponnusamy R, Diaz-Ramirez LG, Gill TM, Sesaki H, Mucke L, Nakamura K. Cell Death Dis. 2015 Apr 16; 6:e1725.
- Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. Dubal DB, Zhu L, Sanchez PE, Worden K, Broestl L, Johnson E, Ho K, Yu GQ, Kim D, Betourne A, Kuro-O M, Masliah E, Abraham CR, Mucke L. J Neurosci. 2015 Feb 11; 35(6):2358-71.
- Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Orr AG, Hsiao EC, Wang MM, Ho K, Kim DH, Wang X, Guo W, Kang J, Yu GQ, Adame A, Devidze N, Dubal DB, Masliah E, Conklin BR, Mucke L. Nat Neurosci. 2015 Mar; 18(3):423-34.
- Tau reduction diminishes spatial learning and memory deficits after mild repetitive traumatic brain injury in mice. Cheng JS, Craft R, Yu GQ, Ho K, Wang X, Mohan G, Mangnitsky S, Ponnusamy R, Mucke L. PLoS One. 2014; 9(12):e115765.
- Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME, Mucke L, Farese RV, Gan L. Nat Med. 2014 Oct; 20(10):1157-64.
- Tau reduction prevents disease in a mouse model of Dravet syndrome. Gheyara AL, Ponnusamy R, Djukic B, Craft RJ, Ho K, Guo W, Finucane MM, Sanchez PE, Mucke L. Ann Neurol. 2014 Sep; 76(3):443-56.
- Life extension factor klotho enhances cognition. Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D, Sturm VE, Kim D, Klein E, Yu GQ, Ho K, Eilertson KE, Yu L, Kuro-o M, De Jager PL, Coppola G, Small GW, Bennett DA, Kramer JH, Abraham CR, Miller BL, Mucke L. Cell Rep. 2014 May 22; 7(4):1065-76.
- Seizures and epileptiform activity in the early stages of Alzheimer disease. Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. JAMA Neurol. 2013 Sep 01; 70(9):1158-66.
- Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β. Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, Kreitzer AC, Mucke L. Nat Neurosci. 2013 May; 16(5):613-21.
- Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L. Neurobiol Aging. 2013 Jun; 34(6):1523-9.
- Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, Yu GQ, Masliah E, Mucke L. PLoS One. 2012; 7(9):e45881.
- Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Proc Natl Acad Sci U S A. 2012 Oct 16; 109(42):E2895-903.
- Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Mucke L, Selkoe DJ. Cold Spring Harb Perspect Med. 2012 Jul; 2(7):a006338.
- Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ. Cell. 2012 Apr 27; 149(3):708-21.
- Alzheimer mechanisms and therapeutic strategies. Huang Y, Mucke L. Cell. 2012 Mar 16; 148(6):1204-22.
- Selective targeting of microglia by quantum dots. Minami SS, Sun B, Popat K, Kauppinen T, Pleiss M, Zhou Y, Ward ME, Floreancig P, Mucke L, Desai T, Gan L. J Neuroinflammation. 2012 Jan 24; 9:22.
- Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. Morris M, Koyama A, Masliah E, Mucke L. PLoS One. 2011; 6(12):e29257.
- Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. Cissé M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L. J Neurosci. 2011 Jul 20; 31(29):10427-31.
- The many faces of tau. Morris M, Maeda S, Vossel K, Mucke L. Neuron. 2011 May 12; 70(3):410-26.
- Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L. J Neurosci. 2011 Jan 12; 31(2):700-11.
- Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling. Palop JJ, Mucke L, Roberson ED. Methods Mol Biol. 2011; 670:245-62.
- Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Cissé M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu GQ, Mucke L. Nature. 2011 Jan 06; 469(7328):47-52.
- Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L. Neuron. 2010 Nov 04; 68(3):428-41.
- Tau reduction prevents Abeta-induced defects in axonal transport. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. Science. 2010 Oct 08; 330(6001):198.
- Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Palop JJ, Mucke L. Nat Neurosci. 2010 Jul; 13(7):812-8.
- Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. Buttini M, Masliah E, Yu GQ, Palop JJ, Chang S, Bernardo A, Lin C, Wyss-Coray T, Huang Y, Mucke L. Am J Pathol. 2010 Aug; 177(2):563-9.
- Phospholipase A2 and arachidonic acid in Alzheimer's disease. Sanchez-Mejia RO, Mucke L. Biochim Biophys Acta. 2010 Aug; 1801(8):784-90.
- Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L. J Neurosci. 2010 Jan 06; 30(1):372-81.
- Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. Sun B, Halabisky B, Zhou Y, Palop JJ, Yu G, Mucke L, Gan L. Cell Stem Cell. 2009 Dec 04; 5(6):624-33.
- Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin? Palop JJ, Mucke L. Neuromolecular Med. 2010 Mar; 12(1):48-55.
- Neuroscience: Alzheimer's disease. Mucke L. Nature. 2009 Oct 15; 461(7266):895-7.
- A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. Alzheimers Dement. 2009 Mar; 5(2):85-92.
- Alzheimer's disease: A prion protein connection. Cisse M, Mucke L. Nature. 2009 Feb 26; 457(7233):1090-1.
- Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L. J Neurosci. 2009 Feb 18; 29(7):1977-86.
- Epilepsy and cognitive impairments in Alzheimer disease. Palop JJ, Mucke L. Arch Neurol. 2009 Apr; 66(4):435-40.
- Collagen VI protects neurons against Abeta toxicity. Cheng JS, Dubal DB, Kim DH, Legleiter J, Cheng IH, Yu GQ, Tesseur I, Wyss-Coray T, Bonaldo P, Mucke L. Nat Neurosci. 2009 Feb; 12(2):119-21.
- Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cissé M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L. Nat Neurosci. 2008 Nov; 11(11):1311-8.
- Genes contributing to prion pathogenesis. Tamgüney G, Giles K, Glidden DV, Lessard P, Wille H, Tremblay P, Groth DF, Yehiely F, Korth C, Moore RC, Tatzelt J, Rubinstein E, Boucheix C, Yang X, Stanley P, Lisanti MP, Dwek RA, Rudd PM, Moskovitz J, Epstein CJ, Cruz TD, Kuziel WA, Maeda N, Sap J, Ashe KH, Carlson GA, Tesseur I, Wyss-Coray T, Mucke L, Weisgraber KH, Mahley RW, Cohen FE, Prusiner SB. J Gen Virol. 2008 Jul; 89(Pt 7):1777-1788.
- Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. Meilandt WJ, Yu GQ, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L. J Neurosci. 2008 May 07; 28(19):5007-17.
- Paths of convergence: sirtuins in aging and neurodegeneration. Gan L, Mucke L. Neuron. 2008 Apr 10; 58(1):10-4.
- Abnormal social behaviors in mice lacking Fgf17. Scearce-Levie K, Roberson ED, Gerstein H, Cholfin JA, Mandiyan VS, Shah NM, Rubenstein JL, Mucke L. Genes Brain Behav. 2008 Apr; 7(3):344-54.
- Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Neuron. 2007 Sep 06; 55(5):697-711.
- Spatial cognition and the human navigation network in AD and MCI. deIpolyi AR, Rankin KP, Mucke L, Miller BL, Gorno-Tempini ML. Neurology. 2007 Sep 04; 69(10):986-97.
- Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliväli J, Lesné S, Ashe KH, Muchowski PJ, Mucke L. J Biol Chem. 2007 Aug 17; 282(33):23818-28.
- Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Science. 2007 May 04; 316(5825):750-4.
- Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. Chin J, Massaro CM, Palop JJ, Thwin MT, Yu GQ, Bien-Ly N, Bender A, Mucke L. J Neurosci. 2007 Mar 14; 27(11):2727-33.
- Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Deipolyi AR, Fang S, Palop JJ, Yu GQ, Wang X, Mucke L. Neurobiol Aging. 2008 Feb; 29(2):253-66.
- 100 years and counting: prospects for defeating Alzheimer's disease. Roberson ED, Mucke L. Science. 2006 Nov 03; 314(5800):781-4.
- Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, Mucke L, Masliah E, Wyss-Coray T. J Clin Invest. 2006 Nov; 116(11):3060-9.
- A network dysfunction perspective on neurodegenerative diseases. Palop JJ, Chin J, Mucke L. Nature. 2006 Oct 19; 443(7113):768-73.
- Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L. Neuron. 2006 Sep 21; 51(6):703-14.
- PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Choi DS, Wang D, Yu GQ, Zhu G, Kharazia VN, Paredes JP, Chang WS, Deitchman JK, Mucke L, Messing RO. Proc Natl Acad Sci U S A. 2006 May 23; 103(21):8215-20.
- Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. Esposito L, Raber J, Kekonius L, Yan F, Yu GQ, Bien-Ly N, Puoliväli J, Scearce-Levie K, Masliah E, Mucke L. J Neurosci. 2006 May 10; 26(19):5167-79.
- Alzheimer's disease: A needle from the haystack. Morris R, Mucke L. Nature. 2006 Mar 16; 440(7082):284-5.
- Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. J Neurosci. 2005 Oct 19; 25(42):9694-703.
- Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. Palop JJ, Chin J, Bien-Ly N, Massaro C, Yeung BZ, Yu GQ, Mucke L. J Neurosci. 2005 Oct 19; 25(42):9686-93.
- SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L. J Biol Chem. 2005 Dec 02; 280(48):40364-74.
- High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, Masliah E. J Biol Chem. 2005 Sep 23; 280(38):32957-67.
- Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells. Esposito L, Gan L, Yu GQ, Essrich C, Mucke L. J Neurochem. 2004 Dec; 91(6):1260-74.
- Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L. Nat Med. 2004 Nov; 10(11):1190-2.
- RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern A, Luddy JS, Lue LF, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, Stern DM, Du Yan SS. EMBO J. 2004 Oct 13; 23(20):4096-105.
- Food for thought: essential fatty acid protects against neuronal deficits in transgenic mouse model of AD. Mucke L, Pitas RE. Neuron. 2004 Sep 02; 43(5):596-9.
- Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L. J Neurosci. 2004 May 12; 24(19):4692-7.
- Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y. J Neurosci. 2004 Mar 10; 24(10):2527-34.
- Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. Huang Y, Weisgraber KH, Mucke L, Mahley RW. J Mol Neurosci. 2004; 23(3):189-204.
- Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y. Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10966-71.
- Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Palop JJ, Jones B, Kekonius L, Chin J, Yu GQ, Raber J, Masliah E, Mucke L. Proc Natl Acad Sci U S A. 2003 Aug 05; 100(16):9572-7.
- Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, Mucke L. J Neurosci. 2002 Dec 15; 22(24):10539-48.
- Inflammation in neurodegenerative disease--a double-edged sword. Wyss-Coray T, Mucke L. Neuron. 2002 Aug 01; 35(3):419-32.
- Androgens protect against apolipoprotein E4-induced cognitive deficits. Raber J, Bongers G, LeFevour A, Buttini M, Mucke L. J Neurosci. 2002 Jun 15; 22(12):5204-9.
- beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L. Proc Natl Acad Sci U S A. 2001 Oct 09; 98(21):12245-50.
- TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L. Nat Med. 2001 May; 7(5):612-8.
- Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Mucke L, Yu GQ, McConlogue L, Rockenstein EM, Abraham CR, Masliah E. Am J Pathol. 2000 Dec; 157(6):2003-10.
- Ibuprofen, inflammation and Alzheimer disease. Wyss-Coray T, Mucke L. Nat Med. 2000 Sep; 6(9):973-4.
- High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. J Neurosci. 2000 Jun 01; 20(11):4050-8.
- Alzheimer's disease-like cerebrovascular pathology in transforming growth factor-beta 1 transgenic mice and functional metabolic correlates. Wyss-Coray T, Lin C, von Euw D, Masliah E, Mucke L, Lacombe P. Ann N Y Acad Sci. 2000 Apr; 903:317-23.
- Apolipoprotein E and cognitive performance. Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, Mucke L. Nature. 2000 Mar 23; 404(6776):352-4.
- Hypothalamic-pituitary-adrenal dysfunction in Apoe(-/-) mice: possible role in behavioral and metabolic alterations. Raber J, Akana SF, Bhatnagar S, Dallman MF, Wong D, Mucke L. J Neurosci. 2000 Mar 01; 20(5):2064-71.
- Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Science. 2000 Feb 18; 287(5456):1265-9.
- Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Am J Pathol. 2000 Jan; 156(1):139-50.
- Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Buttini M, Akeefe H, Lin C, Mahley RW, Pitas RE, Wyss-Coray T, Mucke L. Neuroscience. 2000; 97(2):207-10.
- Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. D'hooge R, Franck F, Mucke L, De Deyn PP. Eur J Neurosci. 1999 Dec; 11(12):4398-402.
- Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Huang F, Buttini M, Wyss-Coray T, McConlogue L, Kodama T, Pitas RE, Mucke L. Am J Pathol. 1999 Nov; 155(5):1741-7.
- Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Xu X, Yang D, Wyss-Coray T, Yan J, Gan L, Sun Y, Mucke L. Proc Natl Acad Sci U S A. 1999 Jun 22; 96(13):7547-52.
- Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, Mahley RW. J Neurosci. 1999 Jun 15; 19(12):4867-80.
- Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, Mucke L, Johnson MH, Sofroniew MV. Neuron. 1999 Jun; 23(2):297-308.
- Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):3228-33.
- Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L. Proc Natl Acad Sci U S A. 1998 Sep 01; 95(18):10914-9.
- Amyloid protein precursor stimulates excitatory amino acid transport. Implications for roles in neuroprotection and pathogenesis. Masliah E, Raber J, Alford M, Mallory M, Mattson MP, Yang D, Wong D, Mucke L. J Biol Chem. 1998 May 15; 273(20):12548-54.
- Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, Johnson MH, Sofroniew MV. Cell. 1998 Apr 17; 93(2):189-201.
- Novel role of human CD4 molecule identified in neurodegeneration. Buttini M, Westland CE, Masliah E, Yafeh AM, Wyss-Coray T, Mucke L. Nat Med. 1998 Apr; 4(4):441-6.
- Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. Krucker T, Toggas SM, Mucke L, Siggins GR. Neuroscience. 1998 Apr; 83(3):691-700.
- Dynamic regulation of c-Jun N-terminal kinase activity in mouse brain by environmental stimuli. Xu X, Raber J, Yang D, Su B, Mucke L. Proc Natl Acad Sci U S A. 1997 Nov 11; 94(23):12655-60.
- Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. Raeber AJ, Race RE, Brandner S, Priola SA, Sailer A, Bessen RA, Mucke L, Manson J, Aguzzi A, Oldstone MB, Weissmann C, Chesebro B. EMBO J. 1997 Oct 15; 16(20):6057-65.
- Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L. Nature. 1997 Oct 09; 389(6651):603-6.
- Astroglial overproduction of TGF-beta 1 enhances inflammatory central nervous system disease in transgenic mice . Wyss-Coray T, Borrow P, Brooker MJ, Mucke L. J Neuroimmunol. 1997 Jul; 77(1):45-50.
- Corticotropin-releasing factor and adrenocorticotrophic hormone as potential central mediators of OB effects. Raber J, Chen S, Mucke L, Feng L. J Biol Chem. 1997 Jun 13; 272(24):15057-60.
- Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Masliah E, Westland CE, Rockenstein EM, Abraham CR, Mallory M, Veinberg I, Sheldon E, Mucke L. Neuroscience. 1997 May; 78(1):135-46.
- Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, Mucke L. Brain Res Brain Res Rev. 1997 Feb; 23(1-2):47-61.
- Central nervous system expression of HIV-1 Gp120 activates the hypothalamic-pituitary-adrenal axis: evidence for involvement of NMDA receptors and nitric oxide synthase. Raber J, Toggas SM, Lee S, Bloom FE, Epstein CJ, Mucke L. Virology. 1996 Dec 15; 226(2):362-73.
- Beta-secretase processing of the beta-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes. Zhao J, Paganini L, Mucke L, Gordon M, Refolo L, Carman M, Sinha S, Oltersdorf T, Lieberburg I, McConlogue L. J Biol Chem. 1996 Dec 06; 271(49):31407-11.
- Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein. D'Hooge R, Nagels G, Westland CE, Mucke L, De Deyn PP. Neuroreport. 1996 Nov 04; 7(15-17):2807-11.
- Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. J Neurosci. 1996 Sep 15; 16(18):5795-811.
- Neurite outgrowth on non-permissive substrates in vitro is enhanced by ectopic expression of the neural adhesion molecule L1 by mouse astrocytes. Mohajeri MH, Bartsch U, van der Putten H, Sansig G, Mucke L, Schachner M. Eur J Neurosci. 1996 Jun; 8(6):1085-97.
- Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis. Wyss-Coray T, Masliah E, Toggas SM, Rockenstein EM, Brooker MJ, Lee HS, Mucke L. J Clin Invest. 1996 Feb 01; 97(3):789-98.
- Neurotrophic and neuroprotective effects of hAPP in transgenic mice. Mucke L, Abraham CR, Masliah E. Ann N Y Acad Sci. 1996 Jan 17; 777:82-8.
- Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Toggas SM, Masliah E, Mucke L. Brain Res. 1996 Jan 15; 706(2):303-7.
- Pathogenesis of HIV-1 associated neurodegeneration. Masliah E, Ge N, Mucke L. Crit Rev Neurobiol. 1996; 10(1):57-67.
- Transgenic models in the study of AIDS dementia complex. Toggas SM, Mucke L. Curr Top Microbiol Immunol. 1996; 206:223-41.
- Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. J Biol Chem. 1995 Nov 24; 270(47):28257-67.
- Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo. Rall GF, Mucke L, Oldstone MB. J Exp Med. 1995 Nov 01; 182(5):1201-12.
- Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Race RE, Priola SA, Bessen RA, Ernst D, Dockter J, Rall GF, Mucke L, Chesebro B, Oldstone MB. Neuron. 1995 Nov; 15(5):1183-91.
- Immunization-induced inflammatory infiltration of the central nervous system in transgenic mice expressing a microbial antigen in astrocytes. Borrow P, Cornell JL, Ruppe MD, Mucke L. J Neuroimmunol. 1995 Sep; 61(2):133-49.
- Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggas SM, Rockenstein EM, Mucke L. Am J Pathol. 1995 Jul; 147(1):53-67.
- Differential regulation of a glial fibrillary acidic protein-LacZ transgene in retinal astrocytes and Müller cells. Verderber L, Johnson W, Mucke L, Sarthy V. Invest Ophthalmol Vis Sci. 1995 May; 36(6):1137-43.
- Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. Mucke L, Abraham CR, Ruppe MD, Rockenstein EM, Toggas SM, Mallory M, Alford M, Masliah E. J Exp Med. 1995 Apr 01; 181(4):1551-6.
- gp120 and neurotoxicity in vivo. Lipton SA, Brenneman DE, Silverstein FS, Masliah E, Mucke L. Trends Pharmacol Sci. 1995 Apr; 16(4):122.
- Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: in vivo comparison of distinct GFAP-lacZ transgenes. Johnson WB, Ruppe MD, Rockenstein EM, Price J, Sarthy VP, Verderber LC, Mucke L. Glia. 1995 Mar; 13(3):174-84.
- Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Mucke L, Masliah E, Campbell IL. Curr Top Microbiol Immunol. 1995; 202:187-205.
- Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR. Brain Res. 1994 Dec 15; 666(2):151-67.
- A transgenic mouse model to assess the interaction of cytotoxic T lymphocytes with virally infected, class I MHC-expressing astrocytes. Rall GF, Mucke L, Nerenberg M, Oldstone MB. J Neuroimmunol. 1994 Jun; 52(1):61-8.
- Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Nature. 1994 Jan 13; 367(6459):188-93.
- Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L. Proc Natl Acad Sci U S A. 1993 Nov 01; 90(21):10061-5.
- Astrocytes in infectious and immune-mediated diseases of the central nervous system. Mucke L, Eddleston M. FASEB J. 1993 Oct; 7(13):1226-32.
- Expression of cathepsin G-like and alpha 1-antichymotrypsin-like proteins in reactive astrocytes. Abraham CR, Kanemaru K, Mucke L. Brain Res. 1993 Sep 10; 621(2):222-32.
- Molecular profile of reactive astrocytes--implications for their role in neurologic disease. Eddleston M, Mucke L. Neuroscience. 1993 May; 54(1):15-36.
- Purification and cloning of brain proteases capable of degrading the beta-amyloid precursor protein. Abraham CR, Razzaboni BL, Papastoitsis G, Picard E, Kanemaru K, Meckelein B, Mucke L. Ann N Y Acad Sci. 1992 Dec 31; 674:174-9.
- The expression of major histocompatibility complex (MHC) class I antigens in the brain differs markedly in acute and persistent infections with lymphocytic choriomeningitis virus (LCMV). Mucke L, Oldstone MB. J Neuroimmunol. 1992 Feb; 36(2-3):193-8.
- Viral persistence in neurons explained by lack of major histocompatibility class I expression. Joly E, Mucke L, Oldstone MB. Science. 1991 Sep 13; 253(5025):1283-5.
- Rapid activation of astrocyte-specific expression of GFAP-lacZ transgene by focal injury. Mucke L, Oldstone MB, Morris JC, Nerenberg MI. New Biol. 1991 May; 3(5):465-74.
- Identification of a functional glucocorticoid response element in the phenylethanolamine N-methyltransferase promoter using fusion genes introduced into chromaffin cells in primary culture. Ross ME, Evinger MJ, Hyman SE, Carroll JM, Mucke L, Comb M, Reis DJ, Joh TH, Goodman HM. J Neurosci. 1990 Feb; 10(2):520-30.
- Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Berger JR, Mucke L. Neurology. 1988 Jul; 38(7):1060-5.
- Anterior ectosylvian visual area (AEV) of the cat: physiological properties. Benedek G, Mucke L, Norita M, Albowitz B, Creutzfeldt OD. Prog Brain Res. 1988; 75:245-55.
- Localization of mRNA for phenylethanolamine N-methyltransferase (PNMT) using in situ hybridization. Schalling M, Dagerlind A, Brene S, Petterson R, Kvist S, Brownstein M, Hyman SE, Mucke L, Goodman HM, Joh TH. Acta Physiol Scand. 1987 Dec; 131(4):631-2.
- Clinical management of neuropathic pain. Mucke L, Maciewicz R. Neurol Clin. 1987 Nov; 5(4):649-63.
- Connections of the anterior ectosylvian visual area (AEV). Norita M, Mucke L, Benedek G, Albowitz B, Katoh Y, Creutzfeldt OD. Exp Brain Res. 1986; 62(2):225-40.
- Physiologic and anatomic investigation of a visual cortical area situated in the ventral bank of the anterior ectosylvian sulcus of the cat. Mucke L, Norita M, Benedek G, Creutzfeldt O. Exp Brain Res. 1982; 46(1):1-11.
Contact
Lennart Mucke
Email
415.734.2504
Randi Mott
Administrative Program Manager
415.734.2506
Email
Lab Members
Che-Wei Chang, PhD
Collaborator
Melanie Das, PhD
Staff Research Scientist II
Cassie Doerner
Student Intern
Daniel Gulbranson, PhD
Collaborator
Kaitlyn Ho
Research Scientist
Wenjie Mao, PhD
Postdoctoral Scholar
Lisa McConlogue, PhD
Visiting Scientist
Laura Mitic, PhD
Collaborator
Cathrine Petersen
Graduate Student
Eric Shao, PhD
Staff Research Scientist I
Nicholas Smith, PhD
Postdoctoral Scholar
Neeraj Soni, PhD
Staff Research Scientist I
Meena Subbarayan, PhD
Postdoctoral Scholar
Xin Wang
Research Associate III
Jiaming Wang, MS
Research Associate III
Unekwu Yakubu, PhD
Postdoctoral Scholar
Xing Yu
Research Associate III
Gui-Qiu Yu, MS
Research Scientist
Allie Zahn
Research Associate I